 Connection
Frits Van Rhee to C-Reactive Protein
This is a "connection" page, showing publications Frits Van Rhee has written about C-Reactive Protein.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.353 |
|
|
|
-
Casper C, Chaturvedi S, Munshi N, Wong R, Qi M, Schaffer M, Bandekar R, Hall B, van de Velde H, Vermeulen J, Reddy M, van Rhee F. Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease. Clin Cancer Res. 2015 Oct 01; 21(19):4294-304.
Score: 0.119
-
Liu YC, Stone K, van Rhee F. Siltuximab for multicentric Castleman disease. Expert Rev Hematol. 2014 Oct; 7(5):545-57.
Score: 0.112
-
Rossi JF, Chiang HC, Lu ZY, Levon K, van Rhee F, Kanhai K, Fajgenbaum DC, Klein B. Optimisation of anti-interleukin-6 therapy: Precision medicine through mathematical modelling. Front Immunol. 2022; 13:919489.
Score: 0.048
-
Morra DE, Pierson SK, Shilling D, Nemat S, Appiani C, Guilfoyle M, Tendler C, van Rhee F, Fajgenbaum DC. Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data. Br J Haematol. 2019 01; 184(2):232-241.
Score: 0.037
-
Bartel TB, Haessler J, Brown TL, Shaughnessy JD, van Rhee F, Anaissie E, Alpe T, Angtuaco E, Walker R, Epstein J, Crowley J, Barlogie B. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009 Sep 03; 114(10):2068-76.
Score: 0.019
-
Pineda-Roman M, Barlogie B, Anaissie E, Zangari M, Bolejack V, van Rhee F, Tricot G, Crowley J. High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in 3077 patients. Cancer. 2008 Apr 15; 112(8):1754-64.
Score: 0.018
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|